EVMN8:00 AMEvommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology CongressTrial Results • Phase 2EADV late-breaking oral presentation Thu, Oct 1, 2026, 8:00 AM EDTGevommune.com
EVMN4:05 PMEvommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 CongressPresentation / Abstract • Phase 2Late-breaking oral presentation Thu, Oct 1, 2026, 4:30 PM CESTevommune.com
EVMN5:43 PMEvommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic DermatitisTrial Results • Phase 2Top-line results Tue, Sep 8, 2026evommune.com
EVMN4:05 PMEvommune Reports Second Quarter 2026 Financial Results and Provides Business Highlightsevommune.com
EVMN8:00 AMEvommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine ProphylaxisTrial Start • Phase 2Trial initiation Thu, Jul 30, 2026, 8:00 AM EDTGevommune.com